Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.84 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.84 |
| ▸ | RPTOR | Q8N122 | 12/20 | 0.80 |
| ▸ | MLST8 | Q9BVC4 | 12/20 | 0.80 |
| ▸ | CSF1R | P07333 | 2/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.80 |
| ▸ | FLT4 | P35916 | 1/20 | 0.80 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.80 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.80 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.49 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137357 | 0.99 | MTOR (0.85) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL29522061 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL29390236 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL15001196 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL29391045 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL154869 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL152929 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL15001238 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL152930 | 0.91 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R | |
| SCHEMBL29522271 | 0.90 | MTOR (1.00) | MTORPIK3CARPTORMLST8CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2021000899-A1 | A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-01-07 | — | — | WO | disclosed |
| EP-3660020-A1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3091021-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2740732-B1 | MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | SIGNAL PHARM LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 10/4885RPTOR 3/4885 |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3CA 6/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.